ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Yibo Du

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5078526214. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent efficacy against pancreatic cancer. Co-author DOI 10.1016/j.bcp.2022.115057 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Weijin Sheng · 1 shared paper, 2022 · strength 0.16
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057 ↗
Qingfang Miao · 1 shared paper, 2022 · strength 0.16
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057 ↗
Xiaofei Wang · 1 shared paper, 2022 · strength 0.16
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057 ↗
Yong‐Su Zhen · 1 shared paper, 2022 · strength 0.16
- Paper The recombinant defensin/HSA fusion protein that inhibits NF-κb associated with intensive macropinocytosis shows potent… DOI 10.1016/j.bcp.2022.115057 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.